Oxford Gene Technology (OGT) is a leading global provider of clinical research and diagnostic genomic solutions. The company specializes in offering high-quality DNA FISH probes and next-generation sequencing (NGS) platforms for the detection of genetic aberrations found in cancer and inherited genetic diseases. OGT serves researchers and clinical decision-makers, enabling them to make accurate decisions for each patient through innovative products and comprehensive support.

Operating in the genomic medicine market, OGT collaborates closely with its clients, which include research institutions, clinical laboratories, and healthcare providers. The business model revolves around the sale of proprietary genomic solutions, including NGS platforms, arrays, and FISH probes. Revenue is generated through direct sales, partnerships, and collaborations.

OGT's commitment to quality and innovation is reflected in its extensive product range, designed to advance the future of genetic-based medicine. The company also offers robust customer support to ensure optimal use of its products.

Keywords: genomic solutions, DNA FISH probes, NGS platforms, cancer research, rare disease research, clinical diagnostics, genetic aberrations, healthcare providers, research institutions, innovation.